Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning

Sophie Servais, Frédéric Baron, Yves Beguin *

Department of Medicine, Division of Hematology, University of Liège, Liège, Belgium
Giga-Research, Section of Hematology, University of Liège, Liège, Belgium

1. Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality, limiting its use to younger patients without medical comorbidities. Over the past few years, it has become more evident that the alloreactivity of transplanted donor immunocompetent cells against host tumor cells (graft-versus-tumor effects, GVT effects) plays a major role in eradicating malignancies after allogeneic HSCT. Based on these observations, several groups of investigators have developed reduced intensity (RIC) regimens allowing patients who are ineligible for conventional HSCT to benefit from the potentially curative GVT effects of allogeneic transplantation. Retrospective studies have suggested that, in comparison with myeloablative allogeneic HSCT, in patients aged 40–60 years, RIC HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality leading to similar progression-free and overall survivals. Prospective studies are ongoing to define which patients might most benefit from RIC HSCT, and to increase the anti-tumoral activity of the procedure while reducing the incidence and the severity of acute graft-versus-host disease (GVHD). In this article, we review the current status and perspectives of RIC HSCT.

* Corresponding author. Address: Department of Hematology, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium. Tel.: +32 4 366 72 01; fax: +32 4 366 88 55.
E-mail address: Yves.Beguin@chu.ulg.ac.be (Y. Beguin).

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality, limiting its use to younger patients without medical co-morbidities. Over the past few years, it has become more evident that the alloreactivity of transplanted donor immunocompetent cells against host tumor cells (graft-versus-tumor effects, GVT effects) plays a major role in eradicating malignancies after allogeneic HSCT. Based on these observations, several groups of investigators have developed reduced intensity (RIC) regimens allowing patients who are ineligible for conventional HSCT to benefit from the potentially curative GVT effects of allogeneic transplantation. Retrospective studies have suggested that, in comparison with myeloablative allogeneic HSCT, in patients aged 40–60 years, RIC HSCT was associated with a higher risk of relapse but a lower incidence of transplant-related mortality leading to similar progression-free and overall survivals. Prospective studies are ongoing to define which patients might most benefit from RIC HSCT, and to increase the anti-tumoral activity of the procedure while reducing the incidence and the severity of acute graft-versus-host disease (GVHD). In this article, we review the current status and perspectives of RIC HSCT.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative conditioning is an effective therapy for many patients with hematological diseases. However, myeloablative conditioning regimens have been associated with significant morbidity and mortality, particularly in patients older than 45 years, those affected by other comorbidities or who have been heavily pretreated (more than two lines of conventional chemotherapy or previous HSCT). This is why conventional allogeneic HSCT has been restricted to younger patients (<50–55 years of age) in good medical condition, whereas the median patient age at diagnosis for many hematological malignancies is over 50 years [1].

Allogeneic HSCT initially relied on maximally tolerated doses of systemic chemo-radiotherapy to eradicate malignant cells, while hematopoietic stem cells (HSC) were infused to rescue patients from lethal myeloablation that occurred as side effect [1]. However, it was quickly recognized that the allograft itself conferred immune-mediated antileukemic effects, termed graft-versus-tumor (GVT) effects [2]. The recognition of the importance of GVT effects in the eradication of malignant cells after myeloablative allogeneic HSCT led to the development of reduced intensity (RIC) or truly nonmyeloablative conditioning regimens. RIC allogeneic HSCT is associated with reduced regimen-related toxicities and reduced transplant-related mortality rates. Therefore, it allows patients who are ineligible for conventional allogeneic HSCT to benefit from the potentially curative GVT effects of allogeneic HSCT.
In this article, we would like to propose a brief review of this type of allografting by focusing on the GVT effect. RIC regimens commonly used, the kinetics of engraftment, the incidence and impact of acute and chronic GVHD, and the current results of RIC HSCT in specific diseases.

2. Definition and features of RIC allogeneic HSCT

2.1. Graft-versus-tumor effect

The concept of GVT effects after allogeneic HSCT is supported by several lines of clinical evidence: (1) patients who develop graft-versus-host disease (GVHD) have a lower risk of relapse than those who do not, (2) patients given T-cell depleted grafts or those given grafts from identical twins have higher risks of relapse, and (3) donor lymphocyte infusions can induce complete remissions (CR) in a number of patients who have relapsed hematological malignancies after allogeneic HSCT [3,4]. It has been suggested that the main mechanisms of GVT effects were the recognition of host-specific minor or major histocompatibility antigens (and maybe tumor-specific antigens) by donor T cells, although several observations have also suggested a role for donor NK and B cells [5–9].

After RIC allogeneic HSCT, tumor eradication relies partially (RIC regimens) or nearly entirely (truly nonmyeloablative regimens) on these GVT effects. Antitumor responses may require extended periods of time, with some patients achieving complete remission more than 1 year after HSCT. GVT activity may also vary in intensity depending on the immunogenicity of the tumors and the respective proliferation rates of tumor cells and donor immune cells [10].

2.2. Nonmyeloablative versus reduced intensity conditioning regimens

In comparison with conventional myeloablative conditioning, RIC regimens have been developed with the aim to induce only reversible myelosuppression and less non-hematological toxicity. These regimens exert only low or moderate activity against malignant cells but provide sufficient immune suppression to prevent immediate rejection of the graft and to allow GVT effects [11].

All RIC regimens should not be considered equivalent, since their immunosuppressive and myelosuppressive properties may be different. In particular, one can distinguish RIC regimens and truly nonmyeloablative regimens.

Most RIC regimens combine fludarabine with intermediate doses of alkylating agents such as busulfan, melphalan or thiothepa. These regimens limit graft rejection (fludarabine) but also convey major antitumor effects by themselves with the aim of shrinking and controlling the malignancy (alkylating agents) before the GVT effects can occur [12]. Typical complications of high-dose therapy, such as mucositis, pancytopenia and organ damage can be observed with these RIC regimens but occur less frequently than after myeloablative conditioning.

In contrast, nonmyeloablative regimens rely on optimization of pre- and post-transplant immunosuppression to allow engraftment, while eradication of tumors depends nearly exclusively on GVT effects. The most common nonmyeloablative regimen consist of low-dose (2 Gy) total body irradiation (TBI) with or without fludarabine combined with postgrafting immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP). Other regimens associate cyclophosphamide and fludarabine, or anti-thymocyte globulin (ATG) and total lymphoid irradiation (TLI) (8 Gy) with postgrafting immunosuppression also consisting in MMF and CSP [12]. These types of conditioning regimens produce only mild myelosuppression and little regimen-related toxicity, making them realizable in an outpatient setting [13]. Following nonmyeloablative conditioning, antitumor responses may require extended periods of time. Because of that, nonmyeloablative HSCT is generally not recommended for patients with aggressive malignancies not in good response at the time of HSCT.

It has been suspected that RIC regimens might be associated with better survival than truly nonmyeloablative conditioning because of a possibly lower incidence of relapse and similar non-relapse mortality. However, two recent studies have suggested that it might not be the case. Blaise et al. reported the results of a prospective randomized study comparing outcomes of 139 patients with hematological malignancies given grafts after fludarabine, busulfan (8 mg/kg) and ATG (n = 69) or fludarabine and 2 Gy TBI (n = 70) [14]. With a median follow-up of 4 years, overall survival (the primary endpoint of the study) was similar in the two arms (44% versus 47%, respectively). Further, Mohty et al. compared outcomes of patients with acute myeloid leukemia (AML) in first CR given grafts following low-dose TBI-based nonmyeloablative conditioning (n = 323) versus more intense but still RIC regimens (n = 877) in European group for Blood and Marrow Transplantation (EBMT)-affiliated centers [15]. Two-year disease-free survival was similar in the two groups (50% versus 53%, respectively).

2.3. Engraftment: mixed chimerism and risk of graft rejection

In contrast with allogeneic transplantation after myeloablative conditioning, RIC HSCT usually leads to an initial state of mixed chimerism defined as the coexistence in the bone marrow of hematopoietic cells from host and from donor origin. Eventually, the majority of patients evolve to full donor chimerism. Achievement of full donor T-cell chimerism is strongly correlated with a decreased risk of progression or relapse [16]. Therefore, attempts to convert mixed chimerism into full donor chimerism (for example by using donor lymphocyte infusions) should be considered in some cases.

RIC HSCT is associated with a higher risk of graft rejection compared with conventional regimens. McSweeney et al. reported a 20% graft rejection rate 2–4 months after HSCT with TBI alone as nonmyeloablative conditioning regimen [17]. High levels (>50%) of donor T- and NK-cell chimerism one month after transplantation are associated with a lower risk of graft rejection [13].
3. Transplantation-related morbidity

3.1. Graft-versus-host disease (GVHD)

A number of reports have compared the incidences of acute and chronic GVHD after RIC and after myeloablative allogeneic HSCT. Most have shown a lower incidence of acute GVHD (when acute GVHD was defined as GVHD occurring before day 100) but a similar incidence of chronic GVHD with RIC regimens [18]. The relatively reduced incidence and severity of acute GVHD after RIC transplantation can be explained by the combination of low-intensity pre-transplant conditioning and the initial mixed chimerism that may favor both host-versus-graft and graft-versus-host tolerance [17,18]. However, a number of patients given RIC conditioning experience late acute GVHD (i.e. acute GVHD occurring after day 100), often at the time of conversion from mixed to full donor T-cell chimerism [13,18].

Occurrence of GVHD is strongly associated with graft-versus-tumor effects in patients given myeloablative conditioning [2]. Since nonmyeloablative regimens rely nearly exclusively on GVT effects for tumor eradication, several groups of investigators looked at the impact of GVHD on HSCT outcomes after nonmyeloablative or RIC conditioning. The Seattle group analyzed the impact of acute and chronic GVHD on HSCT outcomes in a cohort of 322 patients given nonmyeloablative HSCT as treatment for various hematological malignancies [16]. Grade II and grade III–IV acute GVHD were not significantly associated with lower risks of progression/relapse, but were instead associated with increased non-relapse mortality and lower progression-free survival. In contrast, occurrence of chronic GVHD correlated with lower risks of relapse in multivariate time-dependent analyses (HR = 0.4, \( P = 0.006 \)) and was associated with significantly better progression-free survival (HR = 0.5, \( P = 0.003 \)). Similar observations were reported by Valcarcel et al., in a cohort of 93 patients given grafts after RIC as treatment for AML or advanced myelodysplastic syndrome (MDS) [19].

3.2. Other toxicities

The profound pancytopenia following myeloablative conditioning is less profound after RIC regimens and patients require fewer platelet and red blood cell transfusions [17,20].

In a high proportion of patients, neutrophil counts remain over 0.5 \( \times 10^9 \) cells/L during the transplant period or the duration of neutropenia is very short (median time 13 days) [20,21]. This is associated with a lower risk of early bacteremia [21,22]. There is no difference in the incidence of fungal infections after RIC transplantation compared with myeloablative conditioning and CMV manifestations are just delayed [21,22].

RIC regimens are well tolerated in terms of mucosal toxicity and tissue (liver, kidney, gastrointestinal tract and lung) damages are significantly reduced (1, 23). Most of them can also prevent some classical long-term toxicity of conventional conditioning regimens (e.g. preservation of fertility).

4. Outcomes and anti-tumoral activity

4.1. Comparison of outcomes after myeloablative or RIC regimens

Three large retrospective studies from the EBMT have compared HSCT outcomes of patients given various myeloablative versus various RIC/nonmyeloablative regimens as treatment for AML, MDS, or chronic lymphocytic leukemia (CLL) (Table 1) [23–25]. Obviously these studies are limited by the fact that fitter patients were probably more often proposed myeloablative regimens, while older and sicker patients were given nonmyeloablative or RIC regimens. Nevertheless, these studies found similar disease-free and overall survivals in the two groups of patients, since non-relapse mortality was lower in nonmyeloablative patients, but relapse rates were lower in myeloablative recipients [23–25].

4.2. Results in specific diseases

4.2.1. Acute leukemias

The largest prospective study of nonmyeloablative HSCT as treatment for AML has been recently reported by the Seattle consortium for 274 patients with AML in first (n = 160) or second (n = 71) CR or with more advanced diseases (n = 43) [26]. The conditioning regimen consisted in fludarabine and 2 Gy TBI. Five-year overall survival was 37% for patients in first CR at the time of HSCT, 34% for those in second CR and 18% for those with more advanced disease. Other factors associated with survival included cytogenetic risk (5-year overall survival of 40% for patients with good/intermediate cytogenetics versus 19% for those with poor risk cytogenetics), and chronic GVHD that was associated with better survival in time-dependent analysis (HR = 0.7, \( P = 0.07 \), due to a 50% reduction in the risk of re-

---

Table 1

<table>
<thead>
<tr>
<th>Authors (reference)</th>
<th>Disease</th>
<th>Relapse (HR (95%CI); P value)</th>
<th>Non-relapse mortality (HR (95%CI), P value)</th>
<th>Progression-free survival (HR (95%CI), P value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aoudjhane [23]</td>
<td>AML</td>
<td>1.78 (1.30–2.43); 0.0003</td>
<td>0.48 (0.33–0.68);&lt;0.001</td>
<td>1.15 (0.90–1.47); 0.24</td>
</tr>
<tr>
<td>Martino [25]</td>
<td>MDS</td>
<td>1.64 (1.20–2.20); 0.001</td>
<td>0.61 (0.41–0.91); 0.015</td>
<td>1.10 (0.80–1.40); 0.9</td>
</tr>
<tr>
<td>Dreger [24]</td>
<td>CLL</td>
<td>2.46 (0.90–6.72); 0.08</td>
<td>0.40 (0.18–0.90); 0.03</td>
<td>0.69 (0.38–1.25); 0.22</td>
</tr>
</tbody>
</table>

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; HR, hazard ratio.
lapse (P = 0.01)). The later observations clearly demonstrate that AML is highly susceptible to GVT effects.

Nonmyeloablative or RIC HSCT is also increasingly used as treatment for patients with acute lymphoblastic leukemia (ALL). Interestingly, preliminary data from two retrospective studies (one from the CIBMTR and one from the EBMT) have showed similar survival in ALL patients given RIC/nonmyeloablative conditioning compared with those given myeloablative conditioning [27]. These encouraging results confirm the existence of graft-versus-ALL effects.

4.2.2. Myelodysplastic syndromes and myeloproliferative disorders

Martino et al. reported the outcomes of 215 patients given one of various RIC or nonmyeloablative conditioning regimens as treatment for MDS (refractory anemia (n = 20) or more advanced MDS (n = 195)) in EBMT-affiliated centers [25]. Three-year incidences of relapse and non-relapse mortality were 45% and 22%, respectively, while 3-year overall survival was 41%. These results seem to be better than those reported by Laport et al. in patients with MDS given grafts after 2 Gy TBI alone or with fludarabine (3-year relapse rate of 41% and 3-year overall survival of 27%), perhaps due to a high incidence of graft rejection among previously untreated patients given low-intensity nonmyeloablative conditioning [28].

More recently, Kroger et al. reported the results of a prospective study of RIC allogeneic HSCT as treatment for 103 patients with myelofibrosis [29]. The conditioning regimen consisted in busulfan (10 mg/kg), fludarabine and ATG. The 5-year incidence of relapse was 29%, while 5-year progression-free and overall survivals were 51% and 67%, respectively.

4.2.3. Lymphomas

A number of studies have evaluated HSCT following reduced intensity or nonmyeloablative conditioning regimens as treatment for patients with advanced lymphoma, including those relapsing after autologous HSCT [30–33]. Graft-versus-tumor effects were particularly impressive in patients with indolent or mantle cell lymphoma, as well as in those with chemosensitive aggressive lymphomas [10]. Further, two recent reports demonstrated that some patients with Hodgkin’s lymphoma relapsing after autologous HSCT could be salvaged with nonmyeloablative/RIC allo-HSCT [34].

4.2.4. Chronic lymphocytic leukemia

Sorror et al. described outcomes in 152 patients (median age 60 years) with CLL (40) or lymphoma (112) who received HSCT from HLA-matched related (n = 84) or unrelated (n = 68) donors after conditioning with 2 Gy TBI alone or combined with fludarabine [35]. With a median follow-up of 4 years, the 3-year rate of non-relapse mortality was 25%, while 3-year overall survival was 53%. These results demonstrate that CLL is remarkably susceptible to GVT effects, and that a significant proportion of patients with fludarabine-refractory CLL might be cured by RIC/nonmyeloablative HSCT.

4.2.5. Multiple myeloma

The role of nonmyeloablative HSCT in patients with multiple myeloma has been controversial. The Intergroupe Francophone du Myelome compared the outcomes of 284 patients with high risk multiple myeloma treated in two separate prospective protocols consisting of either double autologous HSCT or single autologous HSCT followed by RIC allogeneic HSCT [36]. Survival was worse in the autologous/allogeneic arm but this might be due to the fact that allografting was preceded by administration of high doses of ATG that could have abrogated graft-versus-myeloma effects. Bruno et al. compared a protocol that entailed an autologous HSCT followed by an allograft from an HLA-identical sibling (following conditioning with 2 Gy TBI) for all patients with a HLA-identical sibling with a protocol of tandem autologous HSCT for patients without a HLA-identical sibling [37]. After a median follow-up of 45 months, median overall and event-free survivals were longer in the 80 patients with than in the 82 patients without HLA-identical siblings (80 months versus 54 months, P = 0.01; and 35 months versus 29 months, P = 0.02, respectively). Similar results have been reported in an EBMT-sponsored prospective trial using similar conditioning for autologous and allogeneic HSCT [38].

5. Perspectives

Further improvements in the outcome of RIC-HSCT require reinforcing GVT effects while limiting the deleterious effects of GVHD, and in particular acute GVHD.

Strategies aimed at increasing GVT effects are investigating combining disease-targeted therapies such as imatinib, thalidomide, bortezomib, rituximab, azacytidine, or radioabeled monoclonal antibodies as part of the preparative regimen or as maintenance strategies.

One of the biggest challenges for the future of RIC allogeneic HSCT will be to develop protocols to better prevent acute GVHD. Potential approaches include various forms of T-cell depletion of the graft or in vivo T-cell depletion, as well as the use of immuno-regulatory cells such as mesenchymal stem cells, NK/T cells, or regulatory T-cells.

Nonmyeloablative HSCT with CD8-depleted grafts has been evaluated by several groups, resulting in a lower incidence of severe acute GVHD [39]. However, in a recent phase II prospective randomized trial comparing patients receiving unmanipulated or CD8-depleted grafts after nonmyeloablative conditioning, Willems et al. reported a similar incidence of acute GVHD, albeit with less severe acute GVHD, but a higher risk of graft rejection in the CD8-depleted arm [40]. Based on similar concepts, other groups have proposed to reduce GVHD after RIC conditioning by performing in vivo T-cell depletion with ATG or alemtuzumab. These protocols have achieved their goal but have been associated with a higher risk of relapse [41].

Another approach aimed at reducing the incidence of acute GVHD has been developed by the Stanford group. Based on murine experiments, the authors investigated a novel nonmyeloablative regimen that favored the presence of a high proportion of regulatory NK–T cells [42].
regimen consisted of TLI (8 Gy) and ATG (Thymoglobulin, 7.5 mg/kg total dose), and postgrafting immunosuppression with MMF and CSP. The first results in 110 patients with various hematological malignancies indicated that this regimen was indeed associated with a low incidence of grade II–IV acute GVHD (<10%), while GVT effects were apparently preserved.

Other strategies aimed at decreasing the incidence of acute GVHD have focused on mesenchymal stem cells (MSC). MSC are multipotent progenitors within the bone marrow capable of differentiating into various connective tissues and of modulating immune responses by inhibiting T-cell proliferation. Several groups have evaluated the potential of MSC infusions to prevent or to treat acute GVHD after allogeneic HSCT [43]. Recently, Baron et al. have investigated the impact on GVHD occurrence of MSC co-infusion in 20 patients receiving HLA-mismatched allogeneic grafts after nonmyeloablative conditioning [44]. Compared with 16 similar historical controls, MSC co-transplantation was associated with a lower incidence of severe acute GVHD, lower NRM and improved survival.

Other potential avenues for limiting the risk of acute GVHD are based on regulatory T cells (Treg). These immune-regulatory cells are thought to promote allogeneic tolerance. Rezvani et al. have suggested that the graft Treg content and the rate of Treg reconstitution after transplantation may predict the risk of GVHD after HSCT with myeloablative conditioning [45]. Therefore, manipulating Treg numbers early after transplantation may provide a new approach to control acute GVHD in myeloablative as well as RIC settings. Treg infusions after transplantation as well as Treg number expansion by immunoregulatory drugs such as rapamycin are under investigation.

6. Conclusion

Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic hematopoietic stem cell transplantation (HSCT) in patients for whom conventional myeloablative allogeneic HSCT would have been associated with unacceptable risks of non-relapse mortality. This approach relies mainly on graft-versus-tumor effects for tumor eradication. Results after RIC HSCT are generally encouraging in patient with acute myeloid leukemia in complete remission, with myelodysplastic syndromes not in transformation, with indolent and chemotherapy-sensitive aggressive lymphoma and with chronic lymphoid leukemia. At the opposite, advanced aggressive diseases such as acute leukemia not in complete remission, chemotherapy-refractory high-grade lymphoma or multiple myeloma are less responsive to this therapeutic approach alone. For such diseases, previous cytoreduction by chemotherapy or autologous HSCT is generally required. Occurrence of chronic GVHD seems to correlate with a lower risk of relapse and better progression-free survival. However, acute GVHD is not associated with GVT effects after nonmyeloablative conditioning and remains a serious complication of RIC HSCT. Current research attempts at developing new methods to control it.

Disclosure

The authors have no potential conflict of interest.

Acknowledgments

SS is Research Fellow (Televie grant) and FB Senior Research Associate of the National Fund for Scientific Research (F.R.S.-FNRS) Belgium.

References